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PURPOSE: Hereditary nonpolyposis colon cancer is caused
by mutations in DNA mismatch repair genes, predominantly
MLH1 and MSH2. Classic MLH1 mutations cause an ap-
proximately 20-fold increase in colorectal cancer suscepti-
bility. Recently, we identified a hypomorphic allele, MLH1
D132H, which impairs, but does not completely eliminate
the function of MLH1 in tumor suppression. MLH1 D132H
confers an approximately fivefold increase in colorectal
cancer susceptibility and was first described in a cohort of
Israeli colorectal cancer patients, with an estimated allele
frequency of 1.3 percent. Because MLH1 D132H has only
recently been described, the ethnic distribution of this risk
allele is not well understood. This study was undertaken to
determine both the frequencies of this risk allele in ethnic
groups outside of Israel and whether families harboring this
mutation have susceptibility to extracolonic cancers in the
hereditary nonpolyposis colon cancer spectrum. METH-
ODS: We genotyped two independent cohorts: 629 popu-
lation-based colorectal cancer patients ascertained from
clinics in Orange, Imperial, and San Diego Counties, and
515 endometrial cancer patients ascertained from gyneco-
logic oncology clinics in the Midwestern United States. RE-
SULTS: MLH1 D132H was not detected in either study co-
hort, which together totaled more than 1,100 American
colorectal cancer and endometrial cancer patients. CON-
CLUSIONS: The MLH1 D132H risk variant has significantly
lower allele frequency in American compared with Israeli
cancer patients and, alone, is unlikely to explain significant
amounts of American sporadic colorectal cancer or uterine
cancer susceptibility. Genetic testing for the MLH1 D132H
allele exclusively is therefore unlikely to be cost effective
for genetic risk assessment in American population-based
and clinic-based colorectal cancer and endometrial cancer
patients. [Key words: Colorectal cancer; Endometrial can-
cer; Cancer genetics; MLH1]
M utations in the DNA mismatch repair geneMLH1 are a common cause of hereditary non-
polyposis colon cancer (HNPCC).1 Recently, a hypo-
morphic MLH1 allele has been identified that impairs,
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but does not completely eliminate, the roles of MLH1
in tumor suppression (MLH1 D132H).2 Unlike classic
MLH1 mutations, which cause an ∼20-fold increase in
colorectal cancer (CRC),1 MLH1 D132H confers an
∼fivefold increase in CRC risk.2 This risk allele was
first described in Israelis, including members of Ash-
kenazi Jewish, non-Ashkenazi Jewish, Muslim and
Christian Arab, and Druze Christian population sub-
groups, with an estimated allele frequency in CRC
patients approximating 1.3 percent.2 This mutation
also was unusual because it was associated with CRCs
that lack microsatellite instability (MSI), a phenotype
closely associated with classic MLH1 mutations in
HNPCC.2 Because MLH1 D132H has only recently
been described, the ethnic and cancer susceptibility
characteristics of families with identified MLH1
D132H mutations are not well understood. In particu-
lar, it is important to address what are the frequencies
of this risk allele in ethnic groups outside of Israel,
and whether families harboring this mutation have
susceptibility to other cancers, particularly extraco-
lonic cancers in the HNPCC spectrum. Endometrial
cancer is the most common gynecologic malignancy
in the United States and is the most frequent extraco-
lonic cancer in HNPCC.1 Epigenetic silencing of MLH1
(evidenced by methylation of the MLH1 promoter) is
the most frequent cause of microsatellite instability in
sporadic endometrial and colorectal cancers.3,4 Al-
though nearly 20 percent of a large series of endome-
trial cancers studied had epigenetic inactivation of
MLH1,4 the majority of sporadic colorectal and endo-
metrial cancers do not exhibit the MSI phenotype and
the role that the MLH1 D132H variant plays in these
North American patients is unknown.
To understand more precisely the contribution of
MLH1 D132H to sporadic CRC and endometrial can-
cer in the United States, we genotyped two indepen-
dent cohorts: 629 population-based CRC patients as-
certained from clinics in Orange, Imperial, and San
Diego Counties,5 and 515 endometrial cancer patients
ascertained from gynecologic oncology clinics in the
midwestern United States. In both cohorts of CRC and
endometrial cancer patients, together comprising
more than 1,100 Americans, we did not detect MLH1
D132H. Altogether, these data suggest that MLH1
D132H has significantly lower allele frequency in
American compared with Israeli cancer patients.
METHODS
A total of 1,134 CRC patients were ascertained
through the population-based registries of the Cancer
Surveillance Program of Orange County/San Diego
Imperial Organization for Cancer Control. These sub-
jects were diagnosed between 1994 and 1996. De-
tailed information about the population sampling has
been previously described.5 Positive family history
was defined as having at least one first-degree relative
with CRC, or no first-degree relative with CRC, and at
least two maternal or two paternal second-degree
relatives with CRC, or at least three maternal or three
paternal third-degree relatives. DNA was extracted
from blood samples taken from participants. A total of
629 patients had DNA samples available. For endo-
metrial cancer patients, 515 patients were ascertained
through Washington University Gynecology Oncol-
ogy Clinics in Missouri.4
MLH1 D132H analyses of CRC patient samples
were performed in the laboratory of Dr. Steve Lipkin.
Allelic discrimination of the CRC sample set was op-
timized using a custom TaqMan-based SNP Genotyp-
ing assay and the ABI Prism 7900 HT Sequence De-
tection System (Applied Biosystems, Foster City, CA).
Each 5-µl reaction included 2.5 µl of TaqMan Univer-
sal Master Mix® (Roche Molecular Systems Inc.,
Branchburg, NJ), 0.125 µl of assay reagents for Single
Nucleotide Polymorphism (SNP) genotyping from the
Applera Assays-by-Design (Applied Biosystems)
consisting of a 40× mix of unlabeled PCR primers
and TaqMan MGB probes (FAM and VIC dye la-
beled), in addition to 2 ng of genomic DNA diluted to
2.375 µl in dH2O. Primer sequences were as follows:
Forward 5-GTATCTATCTCTCTACTGGATATT-
AATTTGTTATATTTTCTCATTAG-3; Reverse 5-TT-
GCCAGCACATGGTTTAGGA-3; VIC (Reporter 1 Se-
quence) TTCAGTTTTCCATCTGAGTAA; and FAM
(Reporter 2 Sequence) TCAGTTTTCCATGTGAGTAA.
Positive control genomic DNA samples containing
heterozygous MLH1 D132H alleles were used in ev-
ery assay. PCR was performed at denaturing step of
92°C for 15 seconds and annealing step of 60°C for 60
seconds, for 40 cycles, after an initial hold of 95°C for
10 minutes.
For the endometrial cancer cohort, MLH1 D132H
analyses were optimized and performed in the labo-
ratory of Dr. Paul Goodfellow, using the Pyrose-
quencing technique. Briefly, 20-µl PCR reactions were
performed in 96-well plates, each well containing 11
µl of AmpliTaq Gold® PCR Master Mix (Applied Bio-
systems), 0.5-µl each of 4 µM forward and reverse
primers, and 20 ng of genomic DNA. Primer se-
quences were as follows: PCR Forward 5-TCT-
CTTTTCCCCTTGGGATT-3; PCR Reverse 5-TCCC-
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ATGTACCATTCTTACCG-3; Pyrosequencing primer
5-GGGCTTTCAGTTTTCC-3. Positive control geno-
mic DNA (MLH1 D132H heterozygote) was run to
ensure quality control for each 96-well plate reaction
run. PCR was performed with a denaturing step of
95°C for 30 seconds, an annealing step of 60°C for 30
seconds, and an extension step of 72°C for 30 seconds
for 49 cycles after an initial hot start.
RESULTS
Clinical characteristics of the CRC cohort from
Southern California and the endometrial cancer (EC)
patients from Missouri are described in Tables 1 and
2. For CRC patients, the mean age of diagnosis was 59
years. The vast majority (87.6 percent) of this Ameri-
can CRC subject cohort consisted of non-Hispanic
whites. Slightly < three percent (2.7 percent) were of
Jewish ethnicity.5,6 Approximately one-third (30.7
percent) of cohort has a positive family history of
colon or rectal cancer. Almost one-half (48.1 percent)
of them were found to have early localized state of
disease (Stage 0–2) without involvement of adjacent
organs or lymph nodes, but only 7.1 percent of pa-
tients had Stage IV disease. Close to two-thirds (65
percent) of the tumors were located in the sigmoid
colon or rectum. Complete typing of MSI status for
each individual in the cohort is not available at pres-
ent. From the total of 629 DNA samples analyzed,
alleles were determined for 621 patients (98.7 per-
cent). Positive control DNA samples in duplicate from
MLH1 D132H heterozygotes were used in each Taq-
Man assay that was run. In the 621 CRC cases from the
Southern California CRC cohort who were assayable,
0 of 621 MLH1 D132H carriers (0 percent) were de-
tected.
For the endometrial cancer patients, the mean age
of diagnosis was 64.7 years (Table 2). The vast ma-
jority of this cohort were non-Hispanic whites and
only ∼1.8 percent of the endometrial cancer patient
population was of Ashkenazi Jewish ethnicity. Ap-
proximately 15 percent of endometrial cancer pro-
bands have a first-degree or second-degree relative
with colorectal or endometrial cancer. Approximately
80 percent of patients ascertained had endometrioid
cancer. Twenty-nine and one-half percent of EC pa-
tients have tumors that are MSI-H, and 3 percent MSI-
L, similar to our previously described clinic-based
population.3 Of the endometrial tumors that were
MSI-H, 71.7 percent lacked MLH1 expression because
of epigenetic silencing of MLH1, the most common
cause of MSI-H status in this cancer.3,7 From the total
of 527 DNA samples analyzed, alleles were deter-
mined for 515 patients (97.7 percent). Positive control
DNA samples in duplicate from MLH1 D132H hetero-
zygotes were used in each pyrosequencing assay that
Table 1.












Non-Hispanic whites 543 (87.6)
African American 9 (1.4)
Hispanic 28 (4.5)
Asian/Pacific islander 39 (6.3)
Other 1 (0.2)




In situ 43 (6.9)
Localized 257 (41.2)
Regional, direct extension only 112 (17.9)
Regional, lymph nodes only 62 (9.9)
Regional, direct extension and 98 (15.7)
lymph nodes
Distant metastases 44 (7.1)
Unstageable 8 (1.3)
Grade of differentiation
Well differentiated 87 (13.9)
Moderately differentiated 379 (60.8)
Poorly differentiated 67 (10.7)
Unknown 91 (14.6)










Hepatic flexure 21 (3.4)
Transverse 31 (5)
Splenic flexure 17 (2.7)
Descending 32 (5.1)
Pelvic/sigmoid/sigmoid flexure 176 (28.2)
Overlapping lesions of colon 5 (0.8)
Not otherwise specified 6 (1)
Rectosigmoid/rectum 80 (12.8)
Rectum, not otherwise specified 133 (21.3)
Data are numbers with percentages in parentheses.
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was run. In the 515 EC cases from the Missouri EC
cohort who were assayable, 0 of 515 MLH1 D132H
carriers (0 percent) were detected.
DISCUSSION
We analyzed the allele frequencies of MLH1 D132H
in two cohorts of American cancer patients with
HNPCC-related cancers (colorectal and endometrial
cancers). Together, these cohorts comprise more than
1,100 patients, most of who were white or mixed Eu-
ropean ancestry. In a previous study of population-
based Israeli CRC patients, we detected MLH1 D132H
among Ashkenazi Jewish, non-Ashkenazi Jewish,
Muslim and Christian Arab, and Druze Christian pa-
tients with an estimated allele frequency in CRC pa-
tients approximating 1.3 percent.2 If the allele fre-
quency in the American population were similar, we
would expect to find approximately 8 carriers in this
621 American CRC patients, and 7 carriers in the 515
endometrial cancer patients, respectively. However,
the MLH1 D132H variant allele was not detected in
either of these cohorts. The reasons for this difference
in allele frequency could be attributable to differences
in either the ethnic makeup, or to a lesser degree, to
differences in the clinical characteristics of these two
cohorts.
The most striking difference between these cohorts
is the low frequency of Jewish patients in the South-
ern California CRC Cohort analyzed (2.7 percent)5,6
and the Missouri Endometrial Cancer cohort (1.8 per-
cent) compared with the previous Molecular Epide-
miology of Colorectal Cancer (MECC) study (>80 per-
cent) of population-based Israeli CRC.2 In the MECC
population, Jewish patients comprised 85 percent
(Ashkenazi 71 percent, non-Ashkenazi 29 percent).7,8
Additionally, distinct clinical characteristics of the two
cohorts may account for this allele frequency differ-
ences. Approximately 80 percent of the Southern Cali-
fornia CRC cohort was diagnosed at aged 50 years or
older compared with 94 percent of Israeli population
from the MECC Study, and >90 percent of the general
population of the United States.6 Because the average
age at which MLH1 D132H carriers developed CRC
was 69 compared with 59 in this cohort, the overall
younger average age of the American cohort com-
pared with the MECC study population also may con-
tribute to this difference. Only 7.1 percent of this co-
hort has Stage IV disease compared with 21.9 percent
in the general United States population. A consider-
ably higher proportion of familial cases in this South-
ern California sample (30.7 percent) was noted, be-
cause patients with familial risk of CRC makeup
approximately 20 percent of all CRC.8
Although these clinical factors are unlikely to ac-
count for the majority of the observed difference in
allele frequencies, they perhaps indicate different
mechanisms of carcinogenesis in this younger, ear-
lier-staged CRC cohort. For the endometrial cancer
patients, it may be notable that there were no endo-
metrial cancers described in the probands or first-
Table 2.
Clinical Characteristics of the Endometrial Cancer
Patient Cohort
Cases analyzed for the MLH1 515
D132H variant
Mean age (range) 64.7 (26–99)











Well differentiated 229 (44.5)
Moderately differentiated 148 (28.7)
Poorly differentiated 64 (12.4)


























MSI = microsatellite instability.
Data are numbers with percentages in parentheses un-
less otherwise indicated.
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degree and second-degree relatives of the 21 Israeli
families carrying MLH1 D132H.2 Indeed, at this time
there is no direct evidence suggesting increased en-
dometrial cancer susceptibility in MLH1 D132H carri-
ers. We conclude that MLH1 D132H has a very low
frequency in American sporadic CRC and endometrial
cancer patients, mostly of mixed European ancestry.
Future studies will be required to assess the frequen-
cies of this allele in other ethnic groups.
Molecular diagnostic mutation analysis of MLH1
and MSH2 can cost as much as $2,500 per patient.1
Because of this high cost, individual alleles can be
analyzed in specific patient groups to minimize pa-
tient expense (such as the panel of Ashkenazi founder
mutations for BRCA1 and BRCA2, which reduces pa-
tient cost almost tenfold compared with sequencing
of the coding region). Our work suggests that genetic
testing exclusively for the MLH1 D132H allele is un-
likely to be cost effective for genetic risk assessment
in American population-based and clinic-based CRC
and endometrial cancer patients.
CONCLUSIONS
The MLH1 D132H risk variant has significantly
lower allele frequency in American compared with
Israeli cancer patients and is unlikely to explain sig-
nificant amounts of American sporadic CRC and uter-
ine cancer susceptibility. Targeted genetic testing for
MLH1 D132H in isolation is unlikely to prove cost-
effective.
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